

Human CellExp™ B7-2 / CD86, Human Recombinant

CATALOG NO:	7496-10	10 µg
	7496-50	50 µg
	7496-250	250 µg
	7496-1000	1 mg
ALTERNATE NAMES:	CD86, B7-2, B70, CD28LG2, LAB72, MGC34413	
SOURCE:	HEK 293 cells (Ala 24 – Pro 247)	
PURITY:	> 95% by SDS-PAGE	
MOL. WEIGHT:	This protein is fused with a polyhistidine tag at the C-terminus with a calculated MW of 26.8 kDa. The predicted N-terminus is Ala 24. DTT-reduced protein migrates as ~41 kDa due to glycosylation.	
FORM:	Lyophilized	
FORMULATION:	Lyophilized from 0.22 µm filtered solution in PBS pH 7.4	
STORAGE CONDITIONS:	Store at -20°C. After reconstitution, aliquot and store at -80°C for up to 3 months. Avoid repeated freezing and thawing cycles.	
RECONSTITUTION:	Centrifuge the vial prior to opening. Reconstitute in distilled water.	
DESCRIPTION:	Cluster of Differentiation 86 (CD86) also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily. It is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 and CD80 together prime T cells. B7-2 was shown to promote the generation of mature APC (antigen presenting cells) repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB signaling pathway in macrophages. CD86 is thus regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to first-line therapy.	
BIOLOGICAL ACTIVITY:	Measured by its binding ability in a functional ELISA. Immobilized human CD28 at 5 µg/ml (100 µl/well) can bind human biotinylated CD86 with a linear range of 0.08 – 1.25 µg/ml.	




Fig A. SDS-PAGE (4-20%) of Recombinant B7-2/CD86: Recombinant protein loaded under reducing conditions and stained with Coomassie Blue. The protein migrates as ~41 kDa due to glycosylation.

Fig B. Biological activity: Immobilized human CD28 at 5 µg/ml (100 µl/well) can bind human biotinylated CD86 with a linear range of 0.08 – 1.25 µg/ml.

RELATED PRODUCTS:

- Human CellExp™ CD223, human recombinant (Cat. No. 7278-10, -50)
- Human CellExp™ CD71, human recombinant (Cat. No. 7279-10, -50)
- Human CellExp™ CD273, human recombinant (Cat. No. 7369-10, -50)
- Human CellExp™ CD33, human recombinant (Cat. No. 7370-10, -50)
- Human CellExp™ CD36, human recombinant (Cat. No. 7371-10, -50)
- Human CellExp™ CD87, human recombinant (Cat. No. 7372-20, -100)
- Human CellExp™ CD360, human recombinant (Cat. No. 7373-20, -100)
- Human CellExp™ CD244, human recombinant (Cat. No. 7374-10, -50)

FOR RESEARCH USE ONLY! Not to be used on humans.